Pancreatic neuroendocrine tumors, or PNETs, are a form of cancer that invade the hormone-producing cells in the pancreas. While many are benign, PNETs tend to behave unpredictably. And many treatments against malignant PNETs have proven ineffective. Now, a new study suggests that the anti-inflammatory herbal blend Zyflamend could be a promising treatment option. Experiments showed that Zyflamend reduces cell survival and induces cell death in pancreatic cancer cells in a dose-dependent manner. Zyflamend does so by inducing apoptosis, a programmed death sequence initiated by discarded cells. This form of cell death appears to be mediated by the JNK pathway, an important part of inflammatory responses in mammals. Although more work is needed to understand the full effects of this herbal blend in the clinic. These findings suggest that Zyflamend could be a novel add-on therapy for treating pancreatic cancer.